Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 7/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343781 | 1.00 | GPR183 (0.44) | GPR183NPC1RAB9ATDP1CCR2 | |
| SCHEMBL1344863 | 1.00 | GPR183 (0.44) | GPR183NPC1RAB9ATDP1CCR2 | |
| SCHEMBL1343782 | 1.00 | GPR183 (0.44) | GPR183NPC1RAB9ATDP1CCR2 | |
| SCHEMBL1343776 | 1.00 | GPR183 (0.44) | GPR183NPC1RAB9ATDP1CCR2 | |
| SCHEMBL2905074 | 0.92 | GPR183 (0.46) | GPR183NPC1RAB9ATDP1CCR2 | |
| SCHEMBL2905076 | 0.92 | GPR183 (0.46) | GPR183NPC1RAB9ATDP1CCR2 | |
| SCHEMBL2905082 | 0.92 | GPR183 (0.46) | GPR183NPC1RAB9ATDP1CCR2 | |
| SCHEMBL2899676 | 0.90 | GPR183 (0.45) | GPR183NPC1RAB9ATDP1CCR2 | |
| SCHEMBL2897087 | 0.88 | GPR183 (0.45) | GPR183NPC1RAB9ATDP1CCR2 | |
| SCHEMBL1341256 | 0.83 | HRH3 (0.39) | GPR183NPC1RAB9ATDP1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | GPR183 44/4885NPC1 1067/4885RAB9A 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.